Benjamin Weinberg, MD

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Dr. Benjamin Weinberg presents findings from a ctDNA-based analysis of the CALGB/SWOG 80702 trial, showing that circulating tumor DNA status may help identify patients with stage III colon cancer who could benefit from celecoxib added to standard adjuvant chemotherapy, offering a potential biomarker-driven approach to personalized treatment.

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.